Vanguard Personalized Indexing Management LLC Grows Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Vanguard Personalized Indexing Management LLC raised its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 20.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,036 shares of the company’s stock after buying an additional 508 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Medpace were worth $1,250,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the company. Vanguard Group Inc. boosted its stake in Medpace by 5.9% during the 4th quarter. Vanguard Group Inc. now owns 2,556,443 shares of the company’s stock worth $783,626,000 after purchasing an additional 142,591 shares during the period. TD Asset Management Inc boosted its stake in shares of Medpace by 22.9% during the first quarter. TD Asset Management Inc now owns 574,149 shares of the company’s stock worth $232,042,000 after buying an additional 107,108 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Medpace by 38.3% during the second quarter. Renaissance Technologies LLC now owns 443,588 shares of the company’s stock worth $182,692,000 after buying an additional 122,800 shares during the period. Epoch Investment Partners Inc. grew its holdings in shares of Medpace by 15.3% during the first quarter. Epoch Investment Partners Inc. now owns 406,446 shares of the company’s stock worth $164,265,000 after buying an additional 53,983 shares during the last quarter. Finally, Bessemer Group Inc. raised its stake in Medpace by 1.6% during the 1st quarter. Bessemer Group Inc. now owns 394,834 shares of the company’s stock valued at $159,572,000 after acquiring an additional 6,137 shares during the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on MEDP. Robert W. Baird lowered their target price on Medpace from $430.00 to $413.00 and set an “outperform” rating on the stock in a research note on Friday. Mizuho initiated coverage on shares of Medpace in a research note on Tuesday, May 28th. They issued a “buy” rating and a $435.00 price objective on the stock. StockNews.com cut shares of Medpace from a “buy” rating to a “hold” rating in a research note on Wednesday, September 18th. William Blair reiterated an “outperform” rating on shares of Medpace in a research note on Wednesday, September 11th. Finally, Guggenheim reduced their price objective on shares of Medpace from $464.00 to $432.00 and set a “buy” rating for the company in a research report on Wednesday, July 24th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $420.88.

Medpace Trading Down 0.9 %

MEDP stock opened at $365.70 on Monday. The company’s 50-day moving average price is $378.15 and its 200 day moving average price is $391.82. Medpace Holdings, Inc. has a 52 week low of $227.21 and a 52 week high of $459.77. The company has a market cap of $11.33 billion, a P/E ratio of 37.28, a P/E/G ratio of 1.74 and a beta of 1.35.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, July 22nd. The company reported $2.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.54 by $0.21. The business had revenue of $528.10 million during the quarter, compared to the consensus estimate of $528.41 million. Medpace had a return on equity of 55.14% and a net margin of 16.74%. The business’s revenue was up 14.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.93 EPS. On average, equities research analysts expect that Medpace Holdings, Inc. will post 11.66 earnings per share for the current year.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.